Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Urol. 2000 Jun;163(6):1743-6.

Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.

Author information

  • 1Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Abstract

PURPOSE:

We evaluate the quality of life of asymptomatic men with nonmetastatic prostate cancer who receive androgen deprivation therapy.

MATERIALS AND METHODS:

Quality of life was longitudinally evaluated in a cohort of 144 men with locally advanced prostate cancer or prostate specific antigen relapse after local therapy who chose to receive (79 patients) or not to receive (65 patients) androgen deprivation therapy. Androgen deprivation therapy consisted of orchiectomy, leuprolide alone or leuprolide plus flutamide. Multivariate analysis of variance was used to test the effect of different treatment regimens on patient quality of life.

RESULTS:

Men who received androgen suppression had more fatigue, loss of energy, emotional distress and a lower overall quality of life than men who deferred hormone therapy. Combined androgen blockade had a greater adverse effect on quality of life than monotherapy.

CONCLUSIONS:

Androgen deprivation therapy may significantly impair the physical and emotional health of asymptomatic patients with nonmetastatic prostate cancer.

PMID:
10799173
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk